Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AMED Stock Forecast 2026-2027
$100.99
Current Price
$3.32B
Market Cap
Buy 1
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to AMED Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
AMED Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+3.2%
1 Year Change
0.0%
Year-to-Date Change
0.0%
From 52W High of $101.02
+22.9%
From 52W Low of $82.15
📊 TOP ANALYST CALLS
Did AMED Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Amedisys is one of their latest high-conviction picks.
Latest AMED Stock Price Targets & Analyst Predictions
AMED has shown a year-to-date change of 0.0% and a 1-year change of 3.2%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for AMED. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMED Analyst Ratings
1
Buy
4
Hold
1
Sell
AMED Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $100.99
Latest AMED Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMED.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $100.00 |
| Mar 4, 2025 | Stephens & Co. | Scott Fidel | Equal-Weight | Reiterates | $101.00 |
| Feb 12, 2025 | Stephens & Co. | Raj Kumar | Equal-Weight | Reiterates | $101.00 |
| Jul 31, 2024 | Deutsche Bank | Justin Bowers | Hold | Downgrade | $101.00 |
| Jul 25, 2024 | Cantor Fitzgerald | Sarah James | Neutral | Reiterates | $101.00 |
| Jul 1, 2024 | William Blair | Matt Larew | Market Perform | Downgrade | $N/A |
| Apr 25, 2024 | Cantor Fitzgerald | Sarah James | Neutral | Reiterates | $101.00 |
| Mar 26, 2024 | Raymond James | John Ransom | Market Perform | Maintains | $N/A |
| Mar 25, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $100.00 |
| Sep 14, 2023 | Cantor Fitzgerald | Sarah James | Neutral | Maintains | $101.00 |
| Jul 31, 2023 | TD Cowen | Gary Taylor | Market Perform | Maintains | $101.00 |
| Jul 27, 2023 | Credit Suisse | Jonathan Yong | Neutral | Reiterates | $101.00 |
| Jul 6, 2023 | Jefferies | Brian Tanquilut | Hold | Downgrade | $101.00 |
| Jun 28, 2023 | Benchmark | Hold | Downgrade | $N/A | |
| Jun 27, 2023 | Benchmark | Hold | Downgrade | $N/A | |
| Jun 27, 2023 | Truist Securities | Hold | Maintains | $N/A | |
| Jun 7, 2023 | Truist Securities | Hold | Downgrade | $N/A | |
| Jun 6, 2023 | Benchmark | Buy | Reiterates | $N/A | |
| Jun 6, 2023 | Credit Suisse | Neutral | Downgrade | $N/A | |
| Jun 6, 2023 | Cantor Fitzgerald | Neutral | Maintains | $N/A |
Amedisys, Inc. (AMED) Competitors
The following stocks are similar to Amedisys based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amedisys, Inc. (AMED) Financial Data
Amedisys, Inc. has a market capitalization of $3.32B with a P/E ratio of 39.3x. The company generates $2.40B in trailing twelve-month revenue with a 3.6% profit margin.
Revenue growth is +5.2% quarter-over-quarter, while maintaining an operating margin of +11.7% and return on equity of +6.7%.
Valuation Metrics
Market Cap
$3.32B
Enterprise Value
$3.48B
P/E Ratio
39.3x
PEG Ratio
-2.8x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+5.2%
Gross Margin
+44.0%
Operating Margin
+11.7%
Net Margin
+3.6%
EPS Growth
-13.1%
Financial Health
Cash/Price Ratio
+10.2%
Current Ratio
1.4x
Debt/Equity
35.3x
ROE
+6.7%
ROA
+6.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Amedisys, Inc. (AMED) Business Model
About Amedisys, Inc.
What They Do
Provides personalized in-home healthcare services.
Business Model
Amedisys generates revenue by operating three main segments: home health, hospice, and high acuity care. The home health division focuses on delivering skilled nursing and therapy services to patients at home, while the hospice segment offers end-of-life care. High acuity care expands advanced clinical services into homes, allowing for complex case management and palliative care.
Additional Information
With around 19,000 employees and numerous care centers across the U.S., Amedisys collaborates with hospitals and physicians to enhance post-acute and end-of-life care. This positions the company as a key player in the growing trend towards home-based healthcare solutions.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
19,000
CEO
Mr. Richard M. Ashworth
Country
United States
IPO Year
1994
Website
www.amedisys.comAmedisys, Inc. (AMED) Latest News & Analysis
Latest News
Twilio Set to Join S&P MidCap 400
10 months ago
Quick Summary
Twilio Inc. (TWLO) will replace Amedisys Inc. (AMED) in the S&P MidCap 400 effective August 19, 2025, following Amedisys's acquisition by UnitedHealth Group Inc. (UNH).
Why It Matters
Twilio's inclusion in the S&P MidCap 400 can boost its visibility and attract more institutional investment, potentially impacting its stock price positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
UnitedHealth Group will sell 164 hospice and home health locations to address U.S. antitrust concerns regarding its $3.3 billion acquisition of Amedisys, per the Justice Department.
Why It Matters
The divestiture may impact UnitedHealth's growth strategy and future earnings, while addressing regulatory scrutiny, influencing investor confidence and stock performance.
Source: Reuters
Market Sentiment:
Neutral
Quick Summary
AMED's merger with UnitedHealth faces regulatory challenges, with terms favoring UnitedHealth. AMED also faces internal issues affecting its business performance.
Why It Matters
Regulatory issues threaten AMED's merger with UnitedHealth, creating uncertainty. The asymmetric deal terms favor UNH, increasing risk for AMED investors amid internal performance challenges.
Source: Seeking Alpha
Market Sentiment:
Negative
Amedisys (AMED) Q2 Revenue Tops 5%
11 months ago
Quick Summary
Amedisys (AMED) reported a Q2 revenue increase of over 5%.
Why It Matters
Amedisys' Q2 revenue growth exceeding 5% signals strong demand and potential profitability, which may enhance investor confidence and impact stock performance positively.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores provide a systematic approach to identifying high-potential stocks, aiding investors in making informed decisions to enhance portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Amedisys Reports Second Quarter 2025 Financial Results
11 months ago
Quick Summary
Amedisys, Inc. (NASDAQ: AMED) announced its financial results for Q2 and the first half of 2025, ending June 30. Further details on performance were not provided in the excerpt.
Why It Matters
Amedisys, Inc.'s financial results can affect stock performance, investor sentiment, and future growth potential, impacting investment decisions and market valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AMED Stock
What is Amedisys, Inc.'s (AMED) stock forecast for 2027?
Analyst forecasts for Amedisys, Inc. (AMED) are not currently available. The stock is trading at $100.99.
Is AMED stock a good investment in 2027?
According to current analyst ratings, AMED has 1 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $100.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMED stock?
Price predictions from Wall Street analysts for AMED are not currently available. The stock is trading at $100.99.
What is Amedisys, Inc.'s business model?
Amedisys generates revenue by operating three main segments: home health, hospice, and high acuity care. The home health division focuses on delivering skilled nursing and therapy services to patients at home, while the hospice segment offers end-of-life care. High acuity care expands advanced clinical services into homes, allowing for complex case management and palliative care.
What is the highest forecasted price for AMED Amedisys, Inc.?
Price targets from Wall Street analysts for AMED are not currently available. The stock is trading at $100.99.
What is the lowest forecasted price for AMED Amedisys, Inc.?
Price targets from Wall Street analysts for AMED are not currently available. The stock is trading at $100.99.
What is the overall AMED consensus from analysts for Amedisys, Inc.?
The overall analyst consensus for AMED is neutral. Out of 26 Wall Street analysts, 1 rate it as Buy, 4 as Hold, and 1 as Sell.
How accurate are AMED stock price projections?
Stock price projections, including those for Amedisys, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2026 12:48 AM UTC